Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14380840 | 0.84 | SMN1; SMN2 (0.55) | SOAT1SMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10833794 | 0.79 | PSMB5 (0.51) | SOAT1SMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29145674 | 0.79 | LMNA (0.56) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL11068303 | 0.78 | SOAT1 (0.54) | SOAT1SMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL27632879 | 0.78 | SOAT1 (0.54) | SOAT1SMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL27632878 | 0.78 | SOAT1 (0.54) | SOAT1SMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL27653259 | 0.78 | SOAT1 (0.54) | SOAT1SMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14588989 | 0.77 | ATM (0.52) | SMN1; SMN2CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL1703869 | 0.77 | RIPK1 (0.54) | — | |
| SCHEMBL9505332 | 0.77 | ALDH1A1 (0.66) | SOAT1SMN1; SMN2ALDH1A1HTTNCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| EP-1673085-A4 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | SOAT1 4706/4885SMN1; SMN2 4421/4885CYP1A2 3232/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | SOAT1 4706/4885SMN1; SMN2 4421/4885CYP1A2 3232/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | SOAT1 4706/4885SMN1; SMN2 4421/4885CYP1A2 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.